An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis

Trial Profile

An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Biogen
  • Most Recent Events

    • 27 Jun 2017 Interim results (n=163) presented at the 3rd Congress of the European Academy of Neurology
    • 24 May 2017 Planned End Date changed from 1 Mar 2019 to 21 May 2018.
    • 24 May 2017 Planned primary completion date changed from 1 Mar 2019 to 21 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top